WallStSmart

Orthopediatrics Corp (KIDS)vsMerck & Company Inc (MRK)

VS
⚡

Smart Verdict

WallStSmart Research — data-driven comparison

Merck & Company Inc generates 26241% more annual revenue ($66.57B vs $252.72M). MRK leads profitability with a 4.8% profit margin vs -15.7%. MRK earns a higher WallStSmart Score of 36/100 (F).

KIDS

Hold

35

out of 100

Grade: F

Growth: 7.3Profit: 2.0Value: 6.7Quality: 7.5
Piotroski: 4/9Altman Z: 1.27

MRK

Hold

36

out of 100

Grade: F

Growth: 4.0Profit: 4.5Value: 2.0Quality: 5.0
Piotroski: 3/9Altman Z: 2.27
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

KIDSUndervalued (+71.6%)

Margin of Safety

+71.6%

Fair Value

$60.63

Current Price

$30.80

$29.83 discount

UndervaluedFair: $60.63Overvalued
MRKSignificantly Overvalued (-73.7%)

Margin of Safety

-73.7%

Fair Value

$83.64

Current Price

$146.35

$62.71 premium

UndervaluedFair: $83.64Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

KIDS3 strengths · Avg: 8.3/10
Debt/EquityHealth
0.279/10

Conservative balance sheet, low leverage

Price/BookValuation
2.3x8/10

Reasonable price relative to book value

Revenue GrowthGrowth
15.4%8/10

15.4% revenue growth

MRK2 strengths · Avg: 9.0/10
Market CapQuality
$360.08B10/10

Mega-cap, among the largest globally

Free Cash FlowQuality
$4.48B8/10

Generating 4.5B in free cash flow

Areas to Watch

KIDS4 concerns · Avg: 2.8/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$639.69M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
-11.6%2/10

ROE of -11.6% — below average capital efficiency

Free Cash FlowQuality
$-3.12M2/10

Negative free cash flow — burning cash

MRK4 concerns · Avg: 3.3/10
Price/BookValuation
8.6x4/10

Trading at 8.6x book value

Return on EquityProfitability
7.6%3/10

ROE of 7.6% — below average capital efficiency

Profit MarginProfitability
4.8%3/10

4.8% margin — thin

Debt/EquityHealth
1.293/10

Elevated debt levels

Comparative Analysis Report

WallStSmart Research

Bull Case : KIDS

The strongest argument for KIDS centers on Debt/Equity, Price/Book, Revenue Growth. Revenue growth of 15.4% demonstrates continued momentum.

Bull Case : MRK

The strongest argument for MRK centers on Market Cap, Free Cash Flow.

Bear Case : KIDS

The primary concerns for KIDS are EPS Growth, Market Cap, Return on Equity.

Bear Case : MRK

The primary concerns for MRK are Price/Book, Return on Equity, Profit Margin. A P/E of 115.8x leaves little room for execution misses. Thin 4.8% margins leave little buffer for downturns.

Key Dynamics to Monitor

KIDS profiles as a growth stock while MRK is a value play — different risk/reward profiles.

KIDS carries more volatility with a beta of 0.99 — expect wider price swings.

KIDS is growing revenue faster at 15.4% — sustainability is the question.

MRK generates stronger free cash flow (4.5B), providing more financial flexibility.

Bottom Line

MRK scores higher overall (36/100 vs 35/100). KIDS offers better value entry with a 71.6% margin of safety. Both earn "Hold" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Orthopediatrics Corp

HEALTHCARE · MEDICAL DEVICES · USA

OrthoPediatrics Corp. The company is headquartered in Warsaw, Indiana.

Merck & Company Inc

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.

Visit Website →

Want to dig deeper into these stocks?